TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01844687

Intervention type: DRUG
Group type: OTHER
Intervention: CBD
Description: Each subject in the study was tested on eight days, each day receiving a different combination of active/inactive cannabis cigarettes plus 0, 200, 400 or 800 mg of CBD in random order. Cigarettes contained either 0.01 or 5.30% THC. At each visit, participants were given four gelatin capsules containing lactose and 0 or 200 mg of CBD in combinations to achieve scheduled dose level.

Intervention type: DRUG
Group type: OTHER
Intervention: CBD
Description: Each subject in the study was tested on eight days, each day receiving a different combination of active/inactive cannabis cigarettes plus 0, 200, 400 or 800 mg of CBD in random order. Cigarettes contained either 0.01 or 5.30% THC. At each visit, participants were given four gelatin capsules containing lactose and 0 or 200 mg of CBD in combinations to achieve scheduled dose level.

Intervention type: DRUG
Group type: OTHER
Intervention: CBD
Description: Each subject in the study was tested on eight days, each day receiving a different combination of active/inactive cannabis cigarettes plus 0, 200, 400 or 800 mg of CBD in random order. Cigarettes contained either 0.01 or 5.30% THC. At each visit, participants were given four gelatin capsules containing lactose and 0 or 200 mg of CBD in combinations to achieve scheduled dose level.

Intervention type: DRUG
Group type: OTHER
Intervention: CBD
Description: Each subject in the study was tested on eight days, each day receiving a different combination of active/inactive cannabis cigarettes plus 0, 200, 400 or 800 mg of CBD in random order. Cigarettes contained either 0.01 or 5.30% THC. At each visit, participants were given four gelatin capsules containing lactose and 0 or 200 mg of CBD in combinations to achieve scheduled dose level.

Intervention type: DRUG
Group type: OTHER
Intervention: CBD
Description: Each subject in the study was tested on eight days, each day receiving a different combination of active/inactive cannabis cigarettes plus 0, 200, 400 or 800 mg of CBD in random order. Cigarettes contained either 0.01 or 5.30% THC. At each visit, participants were given four gelatin capsules containing lactose and 0 or 200 mg of CBD in combinations to achieve scheduled dose level.
Study: NCT01382368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Acute single dose of 100 mg of sildenafil. Oral intake in tablet form.
Study: NCT03592810

Intervention type: OTHER
Intervention: Settings of the extracorporeal membrane oxygenation (ECMO)
Description: Compare the settings of the ECMO in different European hospitals and relate them to cerebral saturation and neurological outcome, using Cerebral Performance Category (CPC) score
Study: NCT03196154

Intervention type: DIAGNOSTIC_TEST
Intervention: Fasting insulin level
Description: Fasting insulin and C-peptide level measured using LCMS which is then used to calculate the insulin resistance and beta cell function using homeostasis model assessment

Intervention type: DIAGNOSTIC_TEST
Intervention: Fasting insulin level
Description: Fasting insulin and C-peptide level measured using LCMS which is then used to calculate the insulin resistance and beta cell function using homeostasis model assessment
Study: NCT00997893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPA Placebo
Description: oral placebo pill (0mg MPA)
Study: NCT03327974

Intervention type: OTHER
Group type: OTHER
Intervention: DEPASSE Apllication
Description: Application DEPASSE in depressed patients. This application was developed by the laboratory SERVIER, by a scientific committee of psychologists and psychiatrists: Pr. Courtet, Dr Rimlinger and Pr. Swendsen.~Depasse is available for all on the App store and on Googleplay.~This application has several interests:~- The first is the daily monitoring of the symptoms allowing a regular evaluation throught smileys simulating a scale from 1 to 5. The 10 parameters evaluated are: mood, dark ideas, sleep, stress, concentration, social activities, energy, pleasure, motivation and libido.~There is the possibility to generate a graph representing the evolution of these parameters.~Tips adapted to the actual mood are provided related to the dysfunctional parameters.
Study: NCT03196154

Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma drug level
Description: Plasma trough level of metformin and gliclazide will be measured using LCMS to ensure true compliance.

Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma drug level
Description: Plasma trough level of metformin and gliclazide will be measured using LCMS to ensure true compliance.
Study: NCT02373527

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Fasting prior to catheterization
Description: No restriction for oral intake
Study: NCT02827526

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Study: NCT02734927

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: realization of computerized exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: realization of computerized exercises
Study: NCT02767531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orlistat
Description: Orlistat is a gastric and pancreatic lipase inhibitor that is approved by the FDA for weight loss. It is available over-the-counter as 60 mg tablets under the trade name Alli, and available by prescription as 120 mg capsules under the trade name Xenical.
Study: NCT02035124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM 120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Study: NCT00352183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate/Simvastatin
Description: Combination of Fenofibrate and Simvastatin 40mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Simvastatin 40mg
Study: NCT00717886

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: isosulfan blue dye
Description: At the time of surgery, each patient will undergo a subareolar injection of isosulfan blue dye into the ipsilateral breast as routinely performed during a sentinel lymph node mapping for breast cancer. The surgeon will then perform an axillary lymph node dissection in the usual, routine manner. The above differs from standard of care in that patients scheduled for an upfront axillary dissection do not routinely undergo sentinel lymph node mapping- therefore these patients would not normally get any isotope or TSC injections since they already need an ALND. Second, standard sentinel lymph node mapping involves injection of TSC into the affected breast the day prior to surgery or 3 hours before surgery versus injection of TSC into the ipsilateral upper extremity. The protocol specifies day of mapping for patient convenience.
Study: NCT01520753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 70
Description: Administered subcutaneously (s.c., under the skin) at breakfast, lunch and dinner

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 70
Description: Administered subcutaneously (s.c., under the skin) at breakfast and lunch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 50
Description: Administered subcutaneously (s.c., under the skin) at dinner
Study: NCT03716960

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pumpkin Seed Oil
Description: This intervention consisted of 6 weeks of PSO consumption. Subject were supplemented with 3 g/day of PSO which was ingested in the form of 1g capsules with each main meal of the day (breakfast, lunch and dinner).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This intervention consisted of 6 weeks of placebo consumption. Subject consumed 1 capsule of maltodextrin with each main meal of the day to match the dose and number of capsules ingested daily by the PSO group.
Study: NCT02928484

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic mix CBP-004019/C
Description: One capsule per day of the probiotic mix CBP-004019/C during one month.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule per day of the placebo (maltodextrin) during one month.
Study: NCT02182804

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Olympus
Description: narrow band imaging with magnification

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellvizio
Description: probe-based confocal laser endomicroscopy
Study: NCT00941551

Intervention type: DRUG
Intervention: levothyroxine
Description: levothyroxine 75-125 ug/day

Intervention type: DRUG
Intervention: no levothyroxine
Description: observation only without prophylactic levothyroxine
Study: NCT00797563

Intervention type: DEVICE
Group type: OTHER
Intervention: Apollo Blood Glucose Monitoring System
Description: Subjects with diabetes use a new blood glucose monitoring system with capillary blood; healthcare professionals use the new blood glucose monitoring system with subject capillary and venous blood. All results are compared to a laboratory glucose method - Yellow Springs Instrument (YSI).
Study: NCT04769297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual Micro-Dose Ketamine
Description: daily micro-dosing of frontline healthcare workers suffering from acute stress disorder due to the COVID-19 pandemic
Study: NCT00025467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02826213

Intervention type: DEVICE
Intervention: LifePort® perfusion device
Description: Renal Perfusion with LifePort® perfusion device

Intervention type: DEVICE
Intervention: Waves perfusion device
Description: Renal Perfusion with Waves perfusion device
Study: NCT01369550

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SDA soybean oil-containing foods
Description: 3 servings per day of foods containing 500 mg each SDA soybean oil plus 3 x 500 mg high-oleic sunflower oil in softgels per day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: High-oleic sunflower oil containing foods
Description: 3 servings per day of foods containing 500 mg high-oleic sunflower oil plus 3 x 500 mg high-oleic sunflower oil in softgels per day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eicosapentaenoic acid
Description: 3 x 500 mg per day of Eicosapentaenoic acid as an ethyl ester in softgels plus 3 servings per day of high-oleic sunflower oil-containing foods
Study: NCT06127732

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phytosterol supplements
Description: Participants were randomized into two groups to receive diet plus phytosterols (DP) for 12 weeks, followed by a 7-day washout period with a second period of intervention, where treatments were switched, and participants received diet alone (D) and were followed for another 12 weeks.
Study: NCT01763229

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transthoracic echocardiography
Study: NCT02424695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin Enacarbil (GEn)
Description: HORIZANT Extended-Release Tablets containing 600 mg of gabapentin enacarbil are white to off-white, with occasional black/grey spots, oval-shaped tablets debossed with GS LFG, supplied as:~600 mg: NDC 53451-0101-1.The drug will be stored at 25°C (77°F) (excursions permitted 15° to 30°C (59° to 86°F)) Matching placebo will be provided by Xenoport Inc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03080285

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: over-glasses patch
Description: Over-glasses patch (Tomato Eye Patch, Tomato Inc., Busan, South Korea) is applied to the patients. They were prescribed 2 hours of patching per day for the sound eye.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional patch
Description: Conventional patch (Opticlude Eye Patch, 3M, Maplewood, MN, USA) is applied to the patients. They were prescribed 2 hours of patching per day for the sound eye.
Study: NCT02768987

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bright 1 Bodies
Description: A 12-week intensive lifestyle program utilizing group exercise classes adapted for this population, supplemented with coping skills training and diabetes self-management education.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bright 1 Bodies
Description: A 12-week intensive lifestyle program utilizing group exercise classes adapted for this population, supplemented with coping skills training and diabetes self-management education.
Study: NCT03638791

Intervention type: BEHAVIORAL
Intervention: Exposure and response inhibition
Description: Cognitive behavioural therapy designed for treatment of Obsessive-compulsive disorder

Intervention type: BEHAVIORAL
Intervention: Exposure and response inhibition
Description: Cognitive behavioural therapy designed for treatment of Obsessive-compulsive disorder
Study: NCT01578291

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parental information
Description: An informational brochure indicating the study details

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parental information
Description: An informational brochure indicating the study details

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Play therapy
Description: Play therapy with a child life specialist

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Play therapy
Description: Play therapy with a child life specialist
Study: NCT03653481

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oligofructose-enriched Inulin OI
Description: Consumed as a powder, 8g/d for children \<50kg and 16g/d for children ≥50kg, divided in 2 daily doses.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Consumed as a powder, 8g/d for children \<50kg and 16g/d for children ≥50kg, divided in 2 daily doses.
Study: NCT04445168

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-based motivational interviews
Description: 2-year telephone-based motivational interviews to increase physical activity.
Study: NCT03583281

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Capsules containing flax oil
Description: Capsules containing flax oil to provide 4 grams ALA per day for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Capsules containing DHA-enriched fish oil
Description: Capsules containing fish oil to provide 4 grams DHA per day and 0.8 grams EPA per day for 4 weeks
Study: NCT01383278

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-directed 5 A's intervention for smoking
Description: Computer-directed 5 A's intervention for smoking

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Screening and resource provision
Description: Screening and resource provision
Study: NCT02696798

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ixekizumab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT00565864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-thyroxine (L-T4)
Description: L-thyroxine (L-T4) is the intervention for each arm/group. In each arm/group, the dose of L-T4 is adjusted to achieve TSH levels in the randomly assigned arm. L-thyroxine at doses appropriate to attain target TSH levels for the different arms for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-thyroxine (L-T4)
Description: L-thyroxine (L-T4) is the intervention for each arm/group. In each arm/group, the dose of L-T4 is adjusted to achieve TSH levels in the randomly assigned arm. L-thyroxine at doses appropriate to attain target TSH levels for the different arms for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-thyroxine (L-T4)
Description: L-thyroxine (L-T4) is the intervention for each arm/group. In each arm/group, the dose of L-T4 is adjusted to achieve TSH levels in the randomly assigned arm. L-thyroxine at doses appropriate to attain target TSH levels for the different arms for 24 weeks
Study: NCT04491799

Intervention type: DIAGNOSTIC_TEST
Intervention: Fecal calprotectin
Description: Fecal calprotectin is a protein found in human neutrophils, and it is released during active periods of inflammation of intestine. The sensitivity and specificity has been reported at 93% and 96%, respectively in differentiating inflammatory bowel disease from irritable bowel syndrome in outpatient setting.
Study: NCT05347628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLB1004
Description: PLB1004 is a capsule in the form of 10mg and 40mg.
Study: NCT02459626

Intervention type: OTHER
Intervention: Diagnostic P-V-loops and MRI
Description: Invasive assessment of P-V-loops during catheterization for suspected CAD Magnetic resonance Imaging for assessment of myocardial fibrosis and biventricular function

Intervention type: OTHER
Intervention: Diagnostic P-V-loops and MRI
Description: Invasive assessment of P-V-loops during catheterization for suspected CAD Magnetic resonance Imaging for assessment of myocardial fibrosis and biventricular function

Intervention type: OTHER
Intervention: Diagnostic P-V-loops and MRI
Description: Invasive assessment of P-V-loops during catheterization for suspected CAD Magnetic resonance Imaging for assessment of myocardial fibrosis and biventricular function
Study: NCT01409044

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Music listening for the treatment group. Music is from MusicCure selection Dreams. Outocmes are compared to control group who receives no music. Subjects are randomized Post-operatively.
Study: NCT04078451

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: preserve the main cystic artery
Description: The experimental group preserve the main cystic artery, and the control group cut off the main cystic artery
Study: NCT04643886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEM103
Description: Biological

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEM103
Description: Biological
Study: NCT02173613

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: procalcitonine
Description: The recommendations will be based on the level of PCT: 4 levels of advice will be given:~* It is highly recommended to stop antibiotics if PCT \<0.1ng/ml, and the recommended stop if 0.1ng/ml \<PCT \<0.25 ng / ml.~* It is recommended to continue treatment if 0.25 ng / ml \<PCT ng / ml.~* Finally, if the initial PCT greater than 10 ng / ml, a stop will be advised in case of reduction to less than 10% of baseline level.
Study: NCT03579888

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study: NCT04938700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: probiotics
Description: Probiotics as granules can be used for infants and adolescents

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional medical treatment
Description: Treatment for allergic diseases includes anti-allergic drugs, nasal spray hormones, inhaled hormones, external hormones, etc

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conventional medical treatment
Description: Treatment for allergic diseases includes anti-allergic drugs, nasal spray hormones, inhaled hormones, external hormones, etc
Study: NCT02103205

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Formula with low iron concentration (2 mg/L) supplemented with bovine lactoferrin

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Formula with low iron concentration (2mg/L) without lactoferrin

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Formula with normal iron concentration (8 mg/L) without lactoferrin
Study: NCT04130763

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMT capsule
Description: FMT capsules administration starts in the first week of enrollment. Capsules are taken for three consecutive days in the first week. From week 2, anti-PD-1 therapy will be administrated in combination with the maintenance dose of FMT treatment once every two weeks for up to 6 times.
Study: NCT00670345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Patients will receive a slow endovenous infusion of 500 mg of tranexamic acid before surgical incision, followed by 250 mg/h of tranexamic acid by continuous infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients belonging to the control group will receive the same volume of saline infusions.
Study: NCT03955549

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Insight Enhancement Program (IEP)
Description: IEP is comprised of 8 sessions, administered twice weekly, across a one month period. The session duration is 60-90 minutes. IEP will be administered in a group format with 8-12 patients in each group.~During sessions, different topics representing 8 different stages of illness are discussed according to a chronological schedule. These stages are presented on an Illness March Graph (IMG) and include: Stage I: Personality formation, Stage II: Pre onset confusion, Stage III: Prodroma, Stage IV: The illness, Stage V: Resistance, Stage VI: Remission, Stage VII: Maintenance, Stage VIII: Relapse. Patients actively participate through the exchange of their own experiences and interpretations, which are then reinterpreted by the therapist and by the patients themselves.
Study: NCT03078777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine
Description: Fexofenadine will be administered to patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine
Description: Fexofenadine will be administered to patients.
Study: NCT01308138

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: exercise training
Study: NCT01131936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Amlodipine Tablets, 10 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Amlodipine Tablets, 10 mg